Key Points

  • Low FV, accompanied by low fTFPI in F5F8D, has optimal procoagulant activity, and addition of FV to plasma only results in anticoagulation.

  • The use of DDAVP as a potential substitute for FVIII concentrates without FFP infusion is suggested in F5F8D patients with minor bleeding.

Abstract

Combined factor V (FV) and FVIII deficiency (F5F8D) is a rare autosomal-recessive bleeding disorder caused by mutations in lectin mannose binding-1 (LMAN1) and multiple coagulation factor deficiency-2 (MCFD2). Six causative homozygous mutations (5 in LMAN1 and 1 in MCFD2) were identified in 6 patients with F5F8D. A thrombin-generation assay, triggered with tissue factor (1 pM) in F5F8D plasma, paradoxically exhibited enhanced thrombin generation compared with normal plasma. Significantly lower free tissue factor pathway inhibitor (fTFPI) was found in F5F8D patients compared with healthy controls (P < .01). Normalizing tissue factor pathway inhibitor α (TFPIα) in F5F8D plasma greatly delayed and reduced thrombin generation. Increasing FV concentrations by adding plasma FV to F5F8D plasma only caused a gradual decrease in thrombin generation, suggesting that low levels of TFPIα and FV cocontributed to the elevated thrombin generation by reducing anticoagulant effects. On the contrary, thrombin generation in F5F8D platelet-rich plasma (PRP) was significantly lower than in normal controls (P < .05); however, it was fully corrected by normalizing FVIII or after 1-deamino-8-d-arginine vasopressin (DDAVP) infusion, indicating that the hypocoagulable state of F5F8D patients is associated with low FVIII levels. In addition, plasma and platelet FV in F5F8D PRP were sufficient to support normal thrombin generation, and low TFPIα may have no effect on thrombin generation. DDAVP infusion induced a complete response in 5 F5F8D patients and a partial response in the remaining patient. Based on our findings, we suggest that DDAVP may be considered a potential substitute for FVIII concentrates, and fresh-frozen plasma (FFP) infusion may not be necessary for F5F8D patients with minor bleeding challenges.

REFERENCES

REFERENCES
1.
Mannucci
PM
,
Duga
S
,
Peyvandi
F
.
Recessively inherited coagulation disorders
.
Blood
.
2004
;
104
(
5
):
1243
-
1252
.
2.
Zhang
B
,
McGee
B
,
Yamaoka
JS
, et al
.
Combined deficiency of factor V and factor VIII is due to mutations in either LMAN1 or MCFD2
.
Blood
.
2006
;
107
(
5
):
1903
-
1907
.
3.
Zhang
B
,
Cunningham
MA
,
Nichols
WC
, et al
.
Bleeding due to disruption of a cargo-specific ER-to-Golgi transport complex
.
Nat Genet
.
2003
;
34
(
2
):
220
-
225
.
4.
Nichols
WC
,
Seligsohn
U
,
Zivelin
A
, et al
.
Mutations in the ER-Golgi intermediate compartment protein ERGIC-53 cause combined deficiency of coagulation factors V and VIII
.
Cell
.
1998
;
93
(
1
):
61
-
70
.
5.
Viswabandya
A
,
Baidya
S
,
Nair
SC
, et al
.
Clinical manifestations of combined factor V and VIII deficiency: a series of 37 cases from a single center in India
.
Am J Hematol
.
2010
;
85
(
7
):
538
-
539
.
6.
Mansouritorgabeh
H
,
Rezaieyazdi
Z
,
Pourfathollah
AA
,
Rezai
J
,
Esamaili
H
.
Haemorrhagic symptoms in patients with combined factors V and VIII deficiency in north-eastern Iran
.
Haemophilia
.
2004
;
10
(
3
):
271
-
275
.
7.
Shetty
S
,
Madkaikar
M
,
Nair
S
, et al
.
Combined factor V and VIII deficiency in Indian population
.
Haemophilia
.
2000
;
6
(
5
):
504
-
507
.
8.
Peyvandi
F
,
Tuddenham
EG
,
Akhtari
AM
,
Lak
M
,
Mannucci
PM
.
Bleeding symptoms in 27 Iranian patients with the combined deficiency of factor V and factor VIII
.
Br J Haematol
.
1998
;
100
(
4
):
773
-
776
.
9.
Seligsohn
U
,
Zivelin
A
,
Zwang
E
.
Combined factor V and factor VIII deficiency among non-Ashkenazi Jews
.
N Engl J Med
.
1982
;
307
(
19
):
1191
-
1195
.
10.
Sirachainan
N
,
Zhang
B
,
Chuansumrit
A
,
Pipe
S
,
Sasanakul
W
,
Ginsburg
D
.
Combined factor V and factor VIII deficiency in a Thai patient: a case report of genotype and phenotype characteristics
.
Haemophilia
.
2005
;
11
(
3
):
280
-
284
.
11.
Mansouritorghabeh
H
,
Rezaieyazdi
Z
,
Bagheri
M
.
Successful use of factor VIII concentrate and fresh frozen plasma for four dental extractions in an individual with combined factor V and VIII deficiency
.
Transfus Med Hemother
.
2009
;
36
(
2
):
138
-
139
.
12.
Guglielmone
H
,
Minoldo
S
,
Jarchum
G
.
Response to the DDAVP test in a patient with combined deficiency of factor V and factor VIII
.
Haemophilia
.
2009
;
15
(
3
):
838
-
839
.
13.
Mansouritorghabeh
H
,
Shirdel
A
.
Desmopressin acetate as a haemostatic elevator in individuals with combined deficiency of factors V and VIII: a clinical trial
.
J Thromb Haemost
.
2016
;
14
(
2
):
336
-
339
.
14.
Duckers
C
,
Simioni
P
,
Spiezia
L
, et al
.
Low plasma levels of tissue factor pathway inhibitor in patients with congenital factor V deficiency
.
Blood
.
2008
;
112
(
9
):
3615
-
3623
.
15.
Duckers
C
,
Simioni
P
,
Spiezia
L
, et al
.
Residual platelet factor V ensures thrombin generation in patients with severe congenital factor V deficiency and mild bleeding symptoms
.
Blood
.
2010
;
115
(
4
):
879
-
886
.
16.
Santamaria
S
,
Reglińska-Matveyev
N
,
Gierula
M
, et al
.
Factor V has an anticoagulant cofactor activity that targets the early phase of coagulation
.
J Biol Chem
.
2017
;
292
(
22
):
9335
-
9344
.
17.
van Doorn
P
,
Rosing
J
,
Duckers
C
,
Hackeng
TM
,
Simioni
P
,
Castoldi
E
.
Factor V has anticoagulant activity in plasma in the presence of TFPIα: difference between FV1 and FV2
.
Thromb Haemost
.
2018
;
118
(
7
):
1194
-
1202
.
18.
Dahlbäck
B
,
Guo
LJ
,
Livaja-Koshiar
R
,
Tran
S
.
Factor V-short and protein S as synergistic tissue factor pathway inhibitor (TFPIα) cofactors
.
Res Pract Thromb Haemost
.
2017
;
2
(
1
):
114
-
124
.
19.
Rodeghiero
F
,
Tosetto
A
,
Abshire
T
, et al;
ISTH/SSC joint VWF and Perinatal/Pediatric Hemostasis Subcommittees Working Group
.
ISTH/SSC bleeding assessment tool: a standardized questionnaire and a proposal for a new bleeding score for inherited bleeding disorders
.
J Thromb Haemost
.
2010
;
8
(
9
):
2063
-
2065
.
20.
Thomassen
MC
,
Castoldi
E
,
Tans
G
, et al
.
Endogenous factor V synthesis in megakaryocytes contributes negligibly to the platelet factor V pool
.
Haematologica
.
2003
;
88
(
10
):
1150
-
1156
.
21.
Campbell
JE
,
Meledeo
MA
,
Cap
AP
.
Comparative response of platelet fV and plasma fV to activated protein C and relevance to a model of acute traumatic coagulopathy
.
PLoS One
.
2014
;
9
(
6
):
e99181
.
22.
Ding
Q
,
Wang
M
,
Xu
G
, et al
.
Molecular basis and thrombotic manifestations of antithrombin deficiency in 15 unrelated Chinese patients
.
Thromb Res
.
2013
;
132
(
3
):
367
-
373
.
23.
Li
L
,
Wu
X
,
Wu
W
,
Ding
Q
,
Cai
X
,
Wang
X
.
Clinical manifestation and mutation spectrum of 53 unrelated pedigrees with protein S deficiency in China
.
Thromb Haemost
.
2019
;
119
(
3
):
449
-
460
.
24.
Liang
Q
,
Qin
H
,
Ding
Q
, et al
.
Molecular and clinical profile of VWD in a large cohort of Chinese population: application of next generation sequencing and CNVplex technique
.
Thromb Haemost
.
2017
;
117
(
8
):
1534
-
1548
.
25.
Hemker
HC
,
Giesen
P
,
Al Dieri
R
, et al
.
Calibrated automated thrombin generation measurement in clotting plasma
.
Pathophysiol Haemost Thromb
.
2003
;
33
(
1
):
4
-
15
.
26.
Maurissen
LF
,
Castoldi
E
,
Simioni
P
,
Rosing
J
,
Hackeng
TM
.
Thrombin generation-based assays to measure the activity of the TFPI-protein S pathway in plasma from normal and protein S-deficient individuals
.
J Thromb Haemost
.
2010
;
8
(
4
):
750
-
758
.
27.
Castaman
G
,
Lethagen
S
,
Federici
AB
, et al
.
Response to desmopressin is influenced by the genotype and phenotype in type 1 von Willebrand disease (VWD): results from the European Study MCMDM-1VWD
.
Blood
.
2008
;
111
(
7
):
3531
-
3539
.
28.
Morishita
E
,
Asakura
H
,
Saito
M
, et al
.
Elevated plasma levels of free-form of TFPI antigen in hypercholesterolemic patients
.
Atherosclerosis
.
2001
;
154
(
1
):
203
-
212
.
29.
Hansen
JB
,
Grimsgaard
S
,
Huseby
N
,
Sandset
PM
,
Bønaa
KH
.
Serum lipids and regulation of tissue factor-induced coagulation in middle-aged men
.
Thromb Res
.
2001
;
102
(
1
):
3
-
13
.
30.
Bulato
C
,
Novembrino
C
,
Anzoletti
MB
, et al
.
“In vitro” correction of the severe factor V deficiency-related coagulopathy by a novel plasma-derived factor V concentrate
.
Haemophilia
.
2018
;
24
(
4
):
648
-
656
.
31.
Butenas
S
,
van ’t Veer
C
,
Mann
KG
.
Evaluation of the initiation phase of blood coagulation using ultrasensitive assays for serine proteases
.
J Biol Chem
.
1997
;
272
(
34
):
21527
-
21533
.
32.
Al Dieri
R
,
Bloemen
S
,
Kelchtermans
H
,
Wagenvoord
R
,
Hemker
HC
.
A new regulatory function of activated factor V: inhibition of the activation by tissue factor/factor VII(a) of factor X
.
J Thromb Haemost
.
2013
;
11
(
3
):
503
-
511
.
33.
Ndonwi
M
,
Girard
TJ
,
Broze
GJ
Jr
.
The C-terminus of tissue factor pathway inhibitor α is required for its interaction with factors V and Va
.
J Thromb Haemost
.
2012
;
10
(
9
):
1944
-
1946
.
34.
Vincent
LM
,
Tran
S
,
Livaja
R
,
Bensend
TA
,
Milewicz
DM
,
Dahlbäck
B
.
Coagulation factor V(A2440G) causes east Texas bleeding disorder via TFPIα
.
J Clin Invest
.
2013
;
123
(
9
):
3777
-
3787
.
35.
Baugh
RJ
,
Broze
GJ
Jr
,
Krishnaswamy
S
.
Regulation of extrinsic pathway factor Xa formation by tissue factor pathway inhibitor
.
J Biol Chem
.
1998
;
273
(
8
):
4378
-
4386
.
36.
Wood
JP
,
Bunce
MW
,
Maroney
SA
,
Tracy
PB
,
Camire
RM
,
Mast
AE
.
Tissue factor pathway inhibitor-alpha inhibits prothrombinase during the initiation of blood coagulation
.
Proc Natl Acad Sci USA
.
2013
;
110
(
44
):
17838
-
17843
.
37.
van Doorn
P
,
Rosing
J
,
Wielders
SJ
,
Hackeng
TM
,
Castoldi
E
.
The C-terminus of tissue factor pathway inhibitor-α inhibits factor V activation by protecting the Arg1545 cleavage site [published correction appears in J Thromb Haemost. 2019;17(7):1195]
.
J Thromb Haemost
.
2017
;
15
(
1
):
140
-
149
.
38.
Peraramelli
S
,
Thomassen
S
,
Heinzmann
A
, et al
.
Role of exosite binding modulators in the inhibition of Fxa by TFPI
.
Thromb Haemost
.
2016
;
115
(
3
):
580
-
590
.
39.
Tracy
PB
,
Eide
LL
,
Bowie
EJ
,
Mann
KG
.
Radioimmunoassay of factor V in human plasma and platelets
.
Blood
.
1982
;
60
(
1
):
59
-
63
.
40.
Gould
WR
,
Silveira
JR
,
Tracy
PB
.
Unique in vivo modifications of coagulation factor V produce a physically and functionally distinct platelet-derived cofactor: characterization of purified platelet-derived factor V/Va
.
J Biol Chem
.
2004
;
279
(
4
):
2383
-
2393
.
41.
Gould
WR
,
Simioni
P
,
Silveira
JR
,
Tormene
D
,
Kalafatis
M
,
Tracy
PB
.
Megakaryocytes endocytose and subsequently modify human factor V in vivo to form the entire pool of a unique platelet-derived cofactor
.
J Thromb Haemost
.
2005
;
3
(
3
):
450
-
456
.
42.
Monković
DD
,
Tracy
PB
.
Functional characterization of human platelet-released factor V and its activation by factor Xa and thrombin
.
J Biol Chem
.
1990
;
265
(
28
):
17132
-
17140
.
43.
Zhang
B
,
Spreafico
M
,
Zheng
C
, et al
.
Genotype-phenotype correlation in combined deficiency of factor V and factor VIII
.
Blood
.
2008
;
111
(
12
):
5592
-
5600
.
44.
Nesheim
ME
,
Nichols
WL
,
Cole
TL
, et al
.
Isolation and study of an acquired inhibitor of human coagulation factor V
.
J Clin Invest
.
1986
;
77
(
2
):
405
-
415
.
45.
Mast
AE
,
Broze
GJ
Jr
.
Physiological concentrations of tissue factor pathway inhibitor do not inhibit prothrombinase
.
Blood
.
1996
;
87
(
5
):
1845
-
1850
.
46.
Bouchard
BA
,
Chapin
J
,
Brummel-Ziedins
KE
,
Durda
P
,
Key
NS
,
Tracy
PB
.
Platelets and platelet-derived factor Va confer hemostatic competence in complete factor V deficiency
.
Blood
.
2015
;
125
(
23
):
3647
-
3650
.
You do not currently have access to this content.